AR027714A1 - Uso de sales metalicas para estabilizar composiciones de taxanos. - Google Patents

Uso de sales metalicas para estabilizar composiciones de taxanos.

Info

Publication number
AR027714A1
AR027714A1 ARP010101394A ARP010101394A AR027714A1 AR 027714 A1 AR027714 A1 AR 027714A1 AR P010101394 A ARP010101394 A AR P010101394A AR P010101394 A ARP010101394 A AR P010101394A AR 027714 A1 AR027714 A1 AR 027714A1
Authority
AR
Argentina
Prior art keywords
acid
acids
compositions
metal salt
vehicle
Prior art date
Application number
ARP010101394A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of AR027714A1 publication Critical patent/AR027714A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones que contienen un taxano, un vehículo y una sal metálica de un ácido. Los ácidos preferidos incluyen aminoácidos, ácido ascorbico, ácidos grasos tal como ácidos palmíticos, alfa y beta hidroxiácidos tal como ácido cítrico y ácido gluconico, ácido fluorhídrico, ácido clorhídrico, ácidobromhídrico, ácido iodhídrico, ácido benzoico, ácido sulfurico, ácido hidroximetilsulfínico y ácido sulfonico. También se describen métodos para estabilizarcomposiciones de taxano/vehículo y reducir la degradacion de taxanos por ejemplo, durante el almacenamiento. Los métodos comprenden la inclusion de la salmetálica en la composicion de taxano o el pretratamiento del vehículo con la sal metálica, optativamente en combinacion con otros pretratamientos.
ARP010101394A 2000-03-24 2001-03-23 Uso de sales metalicas para estabilizar composiciones de taxanos. AR027714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19180200P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
AR027714A1 true AR027714A1 (es) 2003-04-09

Family

ID=22706985

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010101395A AR027715A1 (es) 2000-03-24 2001-03-23 Composiciones basadas en taxanos y metodos de uso de las mismas
ARP010101394A AR027714A1 (es) 2000-03-24 2001-03-23 Uso de sales metalicas para estabilizar composiciones de taxanos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010101395A AR027715A1 (es) 2000-03-24 2001-03-23 Composiciones basadas en taxanos y metodos de uso de las mismas

Country Status (7)

Country Link
EP (2) EP1408956A1 (es)
JP (2) JP2003528141A (es)
KR (2) KR20030019328A (es)
AR (2) AR027715A1 (es)
AU (2) AU2001247739A1 (es)
CA (2) CA2404370A1 (es)
WO (2) WO2001072300A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710195B2 (en) * 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
JP2005525310A (ja) * 2001-12-28 2005-08-25 イヴァックス リサーチ インコーポレイテッド タキサンを主剤とした組成物およびその使用法
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
WO2006012692A1 (en) * 2004-08-03 2006-02-09 Vital Health Sciences Pty Ltd Carrier for enteral administration
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
CA2597223A1 (en) * 2005-02-10 2006-08-17 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration
EP1690551A3 (en) 2005-02-10 2006-10-18 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration
WO2006133510A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
CA2611831C (en) 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
HUE042678T2 (hu) 2005-08-31 2019-07-29 Abraxis Bioscience Llc Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
US8512761B2 (en) * 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
NZ602572A (en) 2010-03-30 2014-11-28 Phosphagenics Ltd Transdermal delivery patch
NZ603828A (en) 2010-05-03 2015-09-25 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JP5868414B2 (ja) * 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド タキソイドの医薬組成物
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
EP3383371B1 (en) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Pharmaceutical formulation
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법
CN110585189B (zh) * 2019-09-05 2022-12-30 广东艾时代生物科技有限责任公司 三尖杉宁碱在制备治疗疟疾药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
CN1225262A (zh) * 1998-12-09 1999-08-11 延边香料研究所 一种含有紫杉醇的抗癌药物
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
KR20030019327A (ko) 2003-03-06
AU2001247739A1 (en) 2001-10-08
CA2404374A1 (en) 2001-10-04
JP2003528141A (ja) 2003-09-24
AR027715A1 (es) 2003-04-09
WO2001072299A1 (en) 2001-10-04
WO2001072300A1 (en) 2001-10-04
EP1315484A1 (en) 2003-06-04
JP2003528142A (ja) 2003-09-24
EP1408956A1 (en) 2004-04-21
AU2001247726A1 (en) 2001-10-08
CA2404370A1 (en) 2001-10-04
KR20030019328A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
AR027714A1 (es) Uso de sales metalicas para estabilizar composiciones de taxanos.
ES2483725T3 (es) Composición básica cosmética y su uso
AR051404A1 (es) Composiciones de limpieza y desinfectantes
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2523018T3 (es) Ácidos grasos de cadena media aplicables como agentes anti-microbianos
ES2085192B1 (es) Composiciones cosmeticas despigmentantes a base de acido cafeico.
ES2122520T3 (es) Composicion de limpieza con dos partes que comprende al menos un compuesto de peroxido.
PE20010709A1 (es) Metodos y sistemas para el tratamiento del tejido enfermo con composiciones antiinfecciosas
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
PE20070437A1 (es) FORMULACION ACUOSA hFSH
ES2132676T3 (es) Composiciones de peroxigeno.
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
AR014877A1 (es) Composiciones y metodos para inhibir el fotoenvejecimiento de la piel
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
PA8509801A1 (es) Compuestos antibioticos de azalida
AR072123A1 (es) Composiciones que contienen un agente activo solvatado adecuadas para ser dispensadas como un aerosol de gas comprimido
AR052247A1 (es) Un metodo y una composicion cosmetica par inhibir o controlar simultaneamente la transpiracion y/o mal olor axilar y mejorar o controlar el oscurecimiento de la piel
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
AR040093A1 (es) Composicion limpiadora que comprende perlas suspendidas
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
CO4920220A1 (es) Composiciones que contienen compuestos fluoroeter y metodos para inhibir su degradacion en presencia de un acido de lewis
AR049587A1 (es) Compuesto de hidroxilo fosfatado, su uso como hidrotropo y composicion de limpieza que contiene el compuesto fosfatado
AR056475A1 (es) Formulacion solida estable de sertinodl

Legal Events

Date Code Title Description
FA Abandonment or withdrawal